Santen launches Rocklatan^🄬 ophthalmic solution (netarsudil 0.02% and latanoprost 0.005%), in Singapore for the treatment of patients with open-angle glaucoma or ocular hypertension

March 13, 2025, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced that Santen Pharmaceutical Asia Pte. Ltd. has launched Rocklatan^®, a fixed-dose combination (FDC) of netarsudil and latanoprost, in Singapore, following its approval in July 2023 by the Health Sciences Authority. Singapore is the first market in Santen’s Asia business region* to launch Rocklatan^®. This product has been launched in 17 countries, including Germany, the Netherlands, and the Nordics as Roclanda^®.

Glaucoma is a disease that causes damage to the optic nerve, leading to visual field loss. It is a major cause of visual impairment (including decreased vision and blindness) in many countries. Since the disease is progressive and irreversible, early detection and treatment to control progression and visual field loss is crucial. The number of people living with glaucoma worldwide is expected to reach an estimated 111.8 million in 2040.¹ Glaucoma cases in Asia are expected to exceed 80 million by 2040.² Lowering intraocular pressure (IOP) is considered to be the only evidence-based means for inhibiting the progression of visual field loss caused by glaucoma.

Rocklatan^® is a FDC of a Rho kinase inhibitor and a prostaglandin F_2α analogue indicated for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a Rho kinase inhibitor or prostaglandin F_2α analogue provides insufficient IOP reduction.³ By combining netarsudil (200 micrograms/mL), a ROCK inhibitor, with latanoprost (50 micrograms/mL), a proven prostaglandin analogue (PGA) – Rocklatan^® offers complementary mechanisms of action to reduce IOP, increasing aqueous humour outflow through both the trabecular and uveoscleral outflow pathways.³

“Glaucoma is one of the leading causes of blindness. Many people suffer from this serious disease. Santen is committed to being a partner for glaucoma patients. We aim to offer comprehensive solutions for this condition, and Rocklatan^® is a valuable option for both patients and doctors. We are proud of our contributions to patients and society and will continue our efforts to realize Happiness with Vision for all.” – Tomoyuki Yoshida, Head of Asia Business, Santen.

As a specialized company dedicated to eye health, Santen seeks to contribute to the improved quality of life of glaucoma patients by providing more treatment options to the medical community.

References

1. Tham Y-C et al. Ophthalmology. 2014:121(11):2081-2090.
2. Chan EW, et al. Br J Ophthalmol. 2016;100:78–85.
3. Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Prescribing Information.

About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.

Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com